CD274 and acute myeloid leukemia: Current strategies offer alternative immunotherapeutic options, and the adaptive arm of the immune system is largely harnessed (Au et al., 2020), such as checkpoint inhibitors PD1/PD-L1 antibodies, which has been lagging far behind solid tumors for its limited efficacy in AML (Liu, 2021).